Cargando…

Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models

Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruoka, Yasuhiro, Furusawa, Aki, Okada, Ryuhei, Inagaki, Fuyuki, Fujimura, Daiki, Wakiyama, Hiroaki, Kato, Takuya, Nagaya, Tadanobu, Choyke, Peter L., Kobayashi, Hisataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564971/
https://www.ncbi.nlm.nih.gov/pubmed/32937841
http://dx.doi.org/10.3390/vaccines8030528
_version_ 1783595833958072320
author Maruoka, Yasuhiro
Furusawa, Aki
Okada, Ryuhei
Inagaki, Fuyuki
Fujimura, Daiki
Wakiyama, Hiroaki
Kato, Takuya
Nagaya, Tadanobu
Choyke, Peter L.
Kobayashi, Hisataka
author_facet Maruoka, Yasuhiro
Furusawa, Aki
Okada, Ryuhei
Inagaki, Fuyuki
Fujimura, Daiki
Wakiyama, Hiroaki
Kato, Takuya
Nagaya, Tadanobu
Choyke, Peter L.
Kobayashi, Hisataka
author_sort Maruoka, Yasuhiro
collection PubMed
description Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also at least partly mediated by a profound immune response against the tumor. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is widely recognized as a major immune checkpoint protein, which inhibits the immune response against tumors and is therefore, a target for systemic blockade. We investigated the effect of combining tumor-targeted NIR-PIT against the cell-surface antigen, CD44, which is known as a cancer stem cell marker, with a systemic CTLA4 immune checkpoint inhibitor in three syngeneic tumor models (MC38-luc, LL/2, and MOC1). CD44-targeted NIR-PIT combined with CTLA4 blockade showed greater tumor growth inhibition with longer survival compared with CTLA4 blockade alone in all tumor models. NIR-PIT and CTLA4 blockade produced more complete remission in MOC1 tumors (44%) than NIR-PIT and programmed cell death protein 1 (PD-1) blockade (8%), which was reported in our previous paper. However, the combination of NIR-PIT and CTLA4 blockade was less effective in MC38-luc tumors (11%) than the combination of NIR-PIT and PD-1 blockade (70%). Nonetheless, in many cases ineffective results with NIR-PIT and PD-1 blockade were reversed with NIR-PIT and CTLA4 blockade.
format Online
Article
Text
id pubmed-7564971
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75649712020-10-26 Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models Maruoka, Yasuhiro Furusawa, Aki Okada, Ryuhei Inagaki, Fuyuki Fujimura, Daiki Wakiyama, Hiroaki Kato, Takuya Nagaya, Tadanobu Choyke, Peter L. Kobayashi, Hisataka Vaccines (Basel) Article Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also at least partly mediated by a profound immune response against the tumor. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is widely recognized as a major immune checkpoint protein, which inhibits the immune response against tumors and is therefore, a target for systemic blockade. We investigated the effect of combining tumor-targeted NIR-PIT against the cell-surface antigen, CD44, which is known as a cancer stem cell marker, with a systemic CTLA4 immune checkpoint inhibitor in three syngeneic tumor models (MC38-luc, LL/2, and MOC1). CD44-targeted NIR-PIT combined with CTLA4 blockade showed greater tumor growth inhibition with longer survival compared with CTLA4 blockade alone in all tumor models. NIR-PIT and CTLA4 blockade produced more complete remission in MOC1 tumors (44%) than NIR-PIT and programmed cell death protein 1 (PD-1) blockade (8%), which was reported in our previous paper. However, the combination of NIR-PIT and CTLA4 blockade was less effective in MC38-luc tumors (11%) than the combination of NIR-PIT and PD-1 blockade (70%). Nonetheless, in many cases ineffective results with NIR-PIT and PD-1 blockade were reversed with NIR-PIT and CTLA4 blockade. MDPI 2020-09-14 /pmc/articles/PMC7564971/ /pubmed/32937841 http://dx.doi.org/10.3390/vaccines8030528 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Maruoka, Yasuhiro
Furusawa, Aki
Okada, Ryuhei
Inagaki, Fuyuki
Fujimura, Daiki
Wakiyama, Hiroaki
Kato, Takuya
Nagaya, Tadanobu
Choyke, Peter L.
Kobayashi, Hisataka
Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
title Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
title_full Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
title_fullStr Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
title_full_unstemmed Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
title_short Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
title_sort near-infrared photoimmunotherapy combined with ctla4 checkpoint blockade in syngeneic mouse cancer models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564971/
https://www.ncbi.nlm.nih.gov/pubmed/32937841
http://dx.doi.org/10.3390/vaccines8030528
work_keys_str_mv AT maruokayasuhiro nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT furusawaaki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT okadaryuhei nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT inagakifuyuki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT fujimuradaiki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT wakiyamahiroaki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT katotakuya nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT nagayatadanobu nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT choykepeterl nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels
AT kobayashihisataka nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels